News | August 23, 2024
Sun Pharma introduces STARIZO in India for skin infections
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Sun Pharma has obtained rights from MSD to develop, manufacture and commercialise Tedizolid Phosphate in India
Majority of organizations are looking to increase investments in public and hybrid cloud
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
The discussion at the fourth session was centered on the fusion of academic rigor and industrial pragmatism as a key to pioneering solutions for sustainable and prosperous future
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
This transaction is the third acquisition by three different Japanese players in this segment
Subscribe To Our Newsletter & Stay Updated
